ERBB2 and osteosarcoma: Given that higher expression level of MCAM on human osteosarcoma cells than HER2 and EGFRA, a radiolabeled monoclonal antibody targeting MCAM (177Lu-labeled OI-3) has been evaluated to target the osteosarcoma metastases and circulating tumor cells.